BioSpace

Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.

By BioSpace

1 min read
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights